Vol 12, No 7 (July 31, 2023): Translational Lung Cancer Research

Original Article

Radiomic signature accurately predicts the risk of metastatic dissemination in late-stage non-small cell lung cancer
Agata Małgorzata Wilk, Emilia Kozłowska, Damian Borys, Andrea D’Amico, Krzysztof Fujarewicz, Izabela Gorczewska, Iwona Debosz-Suwinska, Rafał Suwinski, Jarosław Smieja, Andrzej Swierniak
Does hyperthermic povidone-iodine lavage increase the apoptotic rate of residual cancer cell in patients with malignant pleural mesothelioma?—a prospective pilot study
Andrea Bille, Hiral Jhala, Leanne Ashrafian, Leanne Allison, Matthew Russell, Roland Fleck, Daisuke Nonaka
Patient-reported impact of symptoms in lung cancer (PRISM-LC)
Anika Varma, Jennifer Weinstein, Jamison Seabury, Spencer Rosero, Christine Zizzi, Nuran Dilek, John Heatwole, Megan Baumgart, Deborah Mulford, Ronald Maggiore, Lainie Conrow, Jennifer C. King, Jacinta Wiens, Chad Heatwole
Monitoring with circulating tumor cells in the perioperative setting of patients with surgically treated stages I–IIIA NSCLC
Yago Garitaonaindia, Ramón Aguado-Noya, Aranzazu Garcia-Grande, Mar Cordoba, Maria Jose Coronado Albi, Jose Luis Campo Cañaveral, Virginia Calvo, Mariola Blanco Clemente, Ruth Álvarez, Marta Peñas, Luis Chara, Ana Royuela, Mariano Provencio
A prospective phase 2 study of expeditious EGFR genotyping and immediate therapeutic initiation through extracellular vesicles (EV)-based bronchoalveolar lavage fluid (BALF) liquid biopsy in advanced NSCLC patients
In Ae Kim, Jae Young Hur, Hee Joung Kim, Wan Seop Kim, Kye Young Lee
Distinct metastatic spread and progression patterns in patients treated with crizotinib for ROS1- and ALK-rearranged non-small cell lung cancer: a single-center retrospective study
Tomoaki Nakamura, Tatsuya Yoshida, Yuki Takeyasu, Ken Masuda, Yuki Sinno, Yuji Matsumoto, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Yuichiro Ohe
Detection of resistance mutations in patients with anaplastic lymphoma kinase-rearranged lung cancer through liquid biopsy
Takaaki Sasaki, Ryohei Yoshida, Kiichi Nitanai, Takashi Watanabe, Toshiyuki Tenma, Ryotaro Kida, Chie Mori, Yasuhiro Umekage, Noriko Hirai, Yoshinori Minami, Shunsuke Okumura
First-line osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer: efficacy and safety during the COVID-19 pandemic
Suganija Lakkunarajah, Pauline T. Truong, Jeffrey N. Bone, Curtis Hughesman, Stephen Yip, Deepu Alex, Jason Hart, Philip Pollock, Sarah Egli, Melissa Clarkson, Mary Lesperance, Doran Ksienski
Learning curve for uniportal thoracoscopic pulmonary segmentectomy: how many procedures are required to acquire expertise?
Natsumi Matsuura, Hitoshi Igai, Fumi Ohsawa, Kazuki Numajiri, Mitsuhiro Kamiyoshihara
Identification of lysosomal genes associated with prognosis in lung adenocarcinoma
Houqiang Li, Xinyu Sha, Wenmiao Wang, Zhanghao Huang, Peng Zhang, Lei Liu, Silin Wang, Youlang Zhou, Shuai He, Jiahai Shi
Diagnostic accuracy and safety of electromagnetic navigation transthoracic needle biopsy under moderate sedation for the diagnosis of peripheral pulmonary lesions
SoJeong Kim, NaYoung Kim, SooJie Chung, JungHyun Kim, InGyu Hyun, JeongHee Choi, HeeSung Lee
Prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio, C-reactive protein, and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy
MinDong Sung, Won Seok Jang, Hae Reong Kim, Ji Ae Park, Sun Min Lim, Hye Ryun Kim, Byoung Chul Cho, Yu Rang Park, Min Hee Hong
Overexpression of MRPL19 in predicting poor prognosis and promoting the development of lung adenocarcinoma
Dong Wei, Daqiang Sun, Rafael Sirera, Muhammad Zubair Afzal, Tracy L. Leong, Xin Li, Yuhang Wang
Risk factors for pulmonary embolism in lung cancer patients with lower limb deep venous thrombosis: a case-control study
Hai-Yang Dong, Min-Si Tong, Juan Wang, Yuan Liu, Guang-Yu Tao, René Horsleben Petersen, Luis Jara-Palomares, Yi Wang, Yan-Bing Sun, Jie Chen

Editorial Commentary

Adoring ADAURA: can we cure lung cancer that harbors an EGFR mutation?
Barbara Melosky
Tarlatamab: a potential new option for recurrent small cell lung cancer
Alfredo Addeo, Giuseppe Luigi Banna, Alex Friedlaender
Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer?
Shruti R. Patel, Joel W. Neal
Long-term benefit of immunotherapy in metastatic non-small cell lung cancer: the tale of the tail
Ayse Ece Cali Daylan, Balazs Halmos
First-line management of advanced non-small-cell lung cancer: can we do better?
Christos Chouaïd, Isabelle Monnet, Jean-Bernard Auliac
ADAURA update: only the end of the beginning
Bharathi Muthusamy, Nathan A. Pennell
Future lung cancer prediction using low-dose chest computed tomography
Imran Ashraf, Soojung Hur, Yongwan Park
Selpercatinib in patients with RET fusion positive non-small cell lung cancer: updated follow-up of the LIBRETTO-001 phase I/II trial
Thomas E. Stinchcombe